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Spectacular Elevations of Serum Alkaline Phosphatase: 
Clinical and Pathological Correlation 
R o y B . Pat ton, M . D . * 
The diseases responsible for extremely high serum alkaline phosphatase aclivily 
in 45 patients were proliferative hone disease (10 patients) and hepato-biliary 
tract disease (35 patients). Conditions found in these patients that are not usually 
thought to cause such high phosphatase levels were: drug-induced cholestasis (6 
patients), non-malignant extra-hepatic bile duct obstruction (3 palienis). biliary 
or portal cirrhosis (5 patients), and primary hyperparathyroidism with generalized 
osteitis fibrosa (I patient). 
Alkaline phosphatase activity is fre-
quently determined in the clinical lab-
oratory with increases in the serum 
content of this enzyme being commonly 
associated with bone disease in which 
there is formation of new bone tissue, 
extra and intrahepatic biliary duct ob-
struction and parenchymatous liver 
disease. Three other rather special con-
ditions may be responsible for ab-
normal elevations of serum alkaline 
phosphatase: (1) The placenta is rich 
in an alkaline phosphatase and this 
accounts for the modest increase in 
the serum content of this enzyme in 
women in the third trimester of preg-
nancy.' (2) Human albumin for injec-
tion is prepared at least in part from 
placentas and persons receiving this 
material may have markedly high phos-
phatase levels from this source.- (3) 
Alkaline phosphatase production by a 
malignant tumor has been reported in 
a patient in whom the serum alkaline 
phosphatase level was elevated.-' 
Increases in phosphatase activity are 
usually in a range of two to ten times 
the upper limit of normal for the re-
••'Department of Pathology 
porting laboratory; values above this 
range are unusual. Recently 1 encoun-
tered a patient with serum alkaline 
phosphatase levels of 73. 80 and 82 
Bodansky units/100 ml. Since the rea-
son for this was not immediately ap-
parent. I was stimulated to find out how 
often spectacularly high serum alkaline 
phosphatase levels are found and, also, 
to evaluate the clinical conditions as-
sociated with these high levels. 
Materials and Methods 
Records of the clinical chemistry 
laboratory of the Henry Ford Hospital 
were searched for patients having 
serum alkaline phosphatase measure-
ments of 50 or more Bodansky units/ 
100 ml during the period from April 
1968 thru March 1969. During this 
time 14,258 measurements of serum 
alkaline phosphatase were made. Many 
of these represented repeat examina-
tions of the same patients. 
The method is adapted for use in an 
automatic analyzer and essentially is 
that of King and Armstrong* with 
modification. Results as determined 
are thus in King-Armstrong units. 
These are divided by a factor of 3.3 
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Table 
Disease processes responsible for extremely high alkaline 
phosphatase activity in 45 patients. 
Disease Patients 
Bone 10 
Carcinoma of the prostate 
with osteoblastic metastases 
Paget's disease of bone 
Primary hyperparathyroidism 
with osteitis fibrosa 
Carcinoma of the breast with 
osteoblastic metastases 
Liver and/or Bile Ducts 35 
Primary or metastatic 
ca rcinoma 
Cirrhosis 
Nonmalignant extra-hepatic 
bile duct obstruction 
Drug-induced cholestasis 
21 
5 
3 
and reported as Bodansky un i t s .The 
range of normal for adults is 1.5-4.0 
Bodansky units/100 ml. When an ab-
normal value is discovered and there 
is sufficient specimen, it is re-tested in 
the chemistry laboratory for the ab-
normal constituent. The abnormal 
value is not reported if the re-test does 
not confirm it. 
It is not possible precisely to convert 
units of alkaline phosphatase activity 
determined by a given method to units 
in a different method. This is due 
mainly to differences in substrate com-
position, incubation time, serum con-
centration and pH of the reaction mix-
ture, as well as to local laboratory 
modifications of original methods. 
Results 
Forty-five patients with serum alka-
line phosphatase measurements of 50 
or more Bodansky units/100 ml were 
found during the 12-month period of 
study. In all of these patients at least 
one other serum, assayed for this con-
stituent, confirmed the high value. 
Twenty-five of the 45 patients had 
values between 50 and 70 units, 14 
were between 70 and 100 units, and 
six had more than 100 units, the highest 
being 361 Bodansky units/100 ml. The 
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clinical records of these patients were 
examined in order to identify the 
disease process accounting for the ex-
tremely high serum alkaline phospha-
tase. Table I shows the kinds of disease 
found and the number of patients in 
each group. 
Proliferative bone disease was re-
sponsible for the high serum alkaline 
phosphatase in ten patients, six of 
whom had carcinoma of the prostate 
gland with osteoblastic bone metas-
tases. Only one of these patients was 
jaundiced. In this patient, no ob-
structive disease and no evidence of 
metastases in the liver were found dur-
ing a common bile duct exploration. 
The jaundice, which subsequently 
cleared, may have been due to drug-
induced cholestasis. Two of the ten 
patients had Paget's disease of bone, 
but no evidence of liver disease. One 
patient had a parathyroid adenoma 
with hyperparathyroidism and general-
ized osteitis fibrosa. She was never 
jaundiced and, at necropsy, there was 
no evidence of liver disease." The tenth 
patient had carcinoma of the breast 
•with osteoblastic bone metastases. 
Three liver scans were done over a 
three-month interval in this patient and 
there was no evidence of metastases. 
She was not jaundiced when the alka-
line phosphatase was markedly ele-
vated. 
In 35 of the 45 patients, the high 
phosphatase was attributed to liver 
and/or biliary tract disease. Malignant 
disease involving the liver and/or the 
extrahepatic biliary system was the 
cause in 21 patients. These cancers 
were primary in the following sites: 
colon and rectum, 7; pancreas, 3; 
stomach, 2; breast, 2; and gallbladder, 
ampulla of Vater, common bile duct. 
liver, duodenum, renal pelvis and 
uterine tube, one each. With the excep-
tion of two patients with adenocarcin-
oma of the colon all of these patients 
were jaundiced at or near the time 
when the serum alkaline phosphatase 
was extremely high. Nineteen of the 21 
patients have since died and nine had 
post mortem examinations. Three of 
these had hepatic abscesses, as well as 
malignancy metastatic to the liver or 
porta hepatis. None of the 21 patients 
had extensive bone metastases and, 
when these were present, they were 
not osteoblastic. 
Of the 14 patients with nonmalig-
nant disease to account for the high 
serum alkaline phosphatase, two had 
primary biliary cirrhosis, two had sec-
ondary biliary cirrhosis and one had 
portal cirrhosis. Extrahepatic bile duct 
obstruction was responsible in three, 
and drug-induced cholestasis was 
thought to be the cause in the other six. 
In one this was considered due to chlor-
promazine and in another to novobio-
cin. One young woman developed jaun-
dice and high serum alkaline phospha-
tase levels while taking a contraceptive 
drug containing an estrogen and a pro-
gestogen. These levels promptly sub-
sided upon discontinuance of the drug. 
No single drug could be implicated in 
three patients who were taking several 
medications. 
One of these, a 49-year-old woman 
with chronic pyelonephritis and renal 
failure, became jaundiced and had 
high serum alkaline phosphatase levels 
during the final eight days of her life. 
No extrahepatic biliary tract obstruc-
tive disease and no malignancy were 
seen at necropsy. There was no evi-
dence of secondary hyperparathyroid-
ism and no significant bone disease. 
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The second, a 70-year-old woman 
with Hodgkin's disease, developed 
jaundice and had a serum alkaline 
phosphatase of 76 Bodansky units/100 
ml while receiving a variety of drugs. 
The abnormal bilirubin and phospha-
tase measurements promptly returned 
to normal after several of the drugs 
were stopped. Eleven months follow-
ing the episode of jaundice, she was 
feeling well, with the Hodgkin's disease 
apparently under control. 
A 64-year-old man with sarcoidosis, 
the final case, presented with jaundice 
and elevated serum alkaline phospha-
tase. No gross liver disease was seen 
at the time of a common bile duct 
exploration. The jaundice gradually 
subsided over a period of several weeks, 
although the serum alkaline phospha-
tase continued to be modestly elevated. 
In this patient, the hyperbilirubinemia 
and high phosphatase were thought due 
to a toxin, probably a drug. 
Comment 
The underlying disease processes re-
sponsible for extremely high serum al-
kaline phosphatase activities are prob-
ably not different from those that cause 
more modest elevations of this enzyme. 
Pathologic conditions likely to be the 
cause are Paget's disease of bone, 
osteoblastic bone metastases, active 
rickets,'' primary and metastatic tumors 
of the liver, hepatic abscesses, granu-
lomatous diseases of the liver and 
hepatic amyloidosis.'' The present study 
indicates that other causes may be drug-
induced cholestasis, non-malignant ex-
trahepatic bile duct obstruction, some 
forms of cirrhosis and primary hyper-
parathyroidism with osteitis fibrosa. 
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